Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Alnylam Pharmaceuticals, Inc.
ALNYHealth technology
$54.9B
Market Cap
Shariah Analysis
Failed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Alnylam Pharmaceuticals, Inc. appears to be Failed.
Business Activity
FYE 2024
Non-Permissible Income (<5%)5.10%
Non-Permissible
$122
Total Income
$2.4K
Revenue Breakdown
Net product revenues
$1.6K
Net revenues from collaborations
$510
Royalty revenue
$92
Interest income
Non-Operating
$122
Non-Compliant: $122
Financial Screening
FYE 2024
Cash (<30%)8.86%
Non-Shariah Cash Items
Cash And Cash Equivalents$966.4M
Other Short Term Investments$1.7B
Liabilities (<30%)4.26%
Non-Shariah Liabilities
Current Capital Lease Obligation$41.9M
Long Term Debt$1B
Long Term Capital Lease Obligation$229.5M
Market Data
Exchange
NASDAQ
CurrencyUSD
CountryUnited States
Last Updated2026-01-13
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
NASDAQ
